CoChat
Sign Up
Cited by 74Smoking Behavior and CessationPharmacovigilance and Adverse Drug ReactionsSubstance Abuse Treatment and Outcomes

Adverse effects and tolerability of medications for the treatment of tobacco use and dependence

Hays, J. Taylor, Ebbert, Jon O.·2010·Drugs
DOI 10.2165/11538190-000000000-00000
Open this paper in CoChat — free account

Abstract

Tobacco use is the leading cause of preventable death and disability in the world. Although gradually declining in most developed countries, the prevalence of tobacco use has increased among developing countries. Treatment for tobacco use and dependence is effective, although long-term abstinence rates remain disappointingly low. In response, new treatments continue to be developed. In addition, many of the pharmacotherapies that have been available for years have found new applications with the use of medication combinations, higher doses and a longer duration of therapy for approved medications. There are now seven medications (nicotine patch, nicotine gum, nicotine lozenge, nicotine inhaler, nicotine nasal spray, bupropion sustained release and varenicline) approved for tobacco dependence treatment in most countries, and many national and professional society practice guidelines recommend their use. Although each of the medications used for tobacco dependence treatment has been rigorously tested for efficacy and safety, broader experience in clinical trials and in observational population-based studies suggests that adverse events associated with these medications are relatively common. Since 2008, two of the medications (varenicline and bupropion) have come under increasing scrutiny because of reports of unexplained serious adverse events (SAEs), including behaviour change, depression, self-injurious thoughts and suicidal behaviour. To date, this association has not been shown to be caused by these medications, but concerns about medication safety continue. Prescribers require a working knowledge of the common adverse effects for all of these medications as well as a more detailed knowledge of the SAE potential. Nicotine replacement therapy (NRT) has been rigorously tested in clinical trials for over 30 years. A number of adverse effects are commonly associated with NRT use, although SAEs are rare. The adverse effects associated with NRT are due to the pharmacological action of nicotine as well as the mode and site of the NRT application. Bupropion has been tested in over 40 controlled clinical trials and has been associated with higher rates of treatment discontinuation due to adverse events than NRTs. A number of SAEs are associated with bupropion and new warnings were recently added to bupropion prescribing information because of observed neuropsychiatric symptoms including suicidal thoughts and behaviours. Varenicline is the most recently approved medication for tobacco dependence treatment and, although proven safe in clinical testing, new safety concerns have arisen based on post-marketing reports. Warnings have been added to the prescribing information for varenicline because of neuropsychiatric symptoms also including suicidal thoughts and behaviours. Informed decision making regarding the use of pharmacotherapy for the treatment of tobacco dependence requires knowledge about the risks of drug treatment that is weighed against the risks of continued tobacco use and the benefits of treatment. Over half of all long-term smokers will die of a tobacco-related disease and the risk of a serious or life-threatening adverse event with tobacco cessation pharmacotherapy is vanishingly small. Pharmacotherapy for tobacco dependence is also among the most cost-effective preventive health interventions. Given these factors, the benefit : risk ratio is strongly in favour of pharmacotherapy for tobacco dependence treatment in virtually all smokers who are motivated to quit.

Integrity signals

Registry

Crossref · 10.2165/11538190-000000000-00000

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Although a causal relationship has not been established, serious adverse events in patients treated with bupropion or varenicline include changes in behavior, depression, self-injurious thoughts, and suicidal behavior.

    “Although a causal relationship has not been established, serious adverse events in patients treated with bupropion or varenicline include changes in behavior, depression, self-injurious thoughts, and suicidal behavior [234, 244].”

    From Mechanistic insights into nicotine withdrawal (2011) · cites this paper as [244]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Hays, J. T., & Ebbert, J. O.
Affiliations
Mayo Clinic (US)
Corresponding author
Hays, J. Taylor
ORCID
Venue
Drugs
Publisher
Springer Science and Business Media LLC
Published
2010-12
Volume
70
Issue
18
Pages
2357-2372
ISSN
0012-6667 (ISSN-L)
DOI
10.2165/11538190-000000000-00000
OpenAlex
W1972302331
Cited by
74
References
79
Citations by year
2026: 1 · 2024: 1 · 2023: 4 · 2022: 2 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 6 · 2015: 10 · 2014: 13 · 2013: 8 · 2012: 12
FWCI
0.87
Type
journal article
Language
en
Open access
closed
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
tobacco use, pharmacotherapy, adverse drug reactions, tolerability, nicotine replacement therapy, bupropion, varenicline, serious adverse events, suicidal ideation, neuropsychiatric symptoms, drug safety, smoking cessation, nicotine patch, nicotine inhaler, nicotine nasal spray, nicotine lozenges, medication combinations, treatment discontinuation
MeSH terms
Varenicline, Benzazepines, Humans, Nicotine, Quinoxalines, Tobacco Use Disorder, Smoking Cessation, Bupropion, Nicotinic Agonists, Dopamine Uptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review